| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:18288313 | IVTH | 0.00000005 - 0.00000025 M | 0.00000005 - 0.00000025 M | Affects retinoic acid metabolism | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00000005 - 0.00000025 M | 0.00000005 - 0.00000025 M | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:19726171 | IVR | 100 mg/L | 100 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/L | 100 mg/L | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:20598115 | IVR | 40 mg/L | 40 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 80 mg/L | 80 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/L | 4 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/L | 4 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/L | 4 mg/L | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/L | 4 mg/L | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/L | 4 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/L | 0.4 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:21560304 | IVR | 0.05 mg/L | 0.05 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/L | 0.2 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/L | 0.2 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/L | 0.2 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/L | 0.2 mg/L | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/L | 0.2 mg/L | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/L | 0.4 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/L | 0.4 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/L | 0.4 mg/L | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/L | 0.4 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/L | 0.4 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/L | 0.4 mg/L | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| PMID:22068553 | IVR | 3 mg/L | 3 mg/L | Increased cholesterol levels | Metabolic endocrine-mediated perturbations |
| IVR | 3 mg/L | 3 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| PMID:24068038 | IVTH | 0.0000005 M | 0.0000005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000005 M | 0.0000005 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000005 M | 0.0000005 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:29118024 | IVR | 50 mg/L | 50 mg/L | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations |
| PMID:30746931 | IVTH | 0.000003 M | 0.000003 M | Affects placental function | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000005 M | 0.0000005 M | Affects placental function | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.